Objectives: The objective of this study was to examine the perspectives of Canadian emergency physicians on the care of patients with opioid use disorders in the emergency department (ED), in particular the real-world facilitators to prescribing buprenorphine/naloxone (BUP) in the ED.

Methods: We conducted semistructured qualitative interviews using a multi-site-focused ethnographic design. Purposive sampling via an existing national research network was used to recruit ED physicians. Interviews were conducted by phone using an interview guide and continued until theoretical data saturation was reached. Interviews were transcribed and analyzed using latent content analysis. Interviews took place between June 21, 2019, and February 11, 2020.

Results: A total of 32 physicians were included in the analysis. Participants had a median of 10 years of experience, and most (29/32) worked in urban settings. Clinical care of patients with opioid use disorder was found to be variable and physician dependent. Although some physicians reported routinely prescribing BUP, others felt that this was outside the clinical scope of emergency medicine. Access to clinical pathways, incentivized training, dedicated human resources, and follow-up care were identified as critical facilitators for supporting BUP prescribing. Participants also identified a shared responsibility between patients and the ED, including the importance of a patient-centered approach that enhanced patient autonomy. ED BUP prescribing became self-reinforcing over time.

Conclusions: Although there remains practice variability among Canadian emergency physicians, successful implementation of ED BUP prescribing has occurred in some locations. Jurisdictions wanting to facilitate BUP uptake should consider providing incentivized training, treatment protocols, dedicated human resources, and streamlined access to follow-up care.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082712PMC
http://dx.doi.org/10.1002/emp2.12409DOI Listing

Publication Analysis

Top Keywords

bup prescribing
12
emergency department
8
canadian emergency
8
emergency physicians
8
care patients
8
patients opioid
8
incentivized training
8
dedicated human
8
human resources
8
follow-up care
8

Similar Publications

Capturing the Full Range of Buprenorphine Treatment Response.

JAMA Psychiatry

December 2024

Division of Alcohol, Drugs, and Addiction, McLean Hospital, Belmont, Massachusetts.

Importance: Reliance on abstinence-based treatment success rules may fail to capture the full continuum of treatment response to buprenorphine plus medical counseling (BUP+MC) for opioid use disorder (OUD).

Objective: To describe patterns of reduction in illicit opioid use of patients both labeled as a success and nonsuccess based on an abstinent-based treatment outcome rule.

Design, Setting, And Participants: This study is a secondary data analysis of 4 harmonized randomized clinical trials on BUP+MC for OUD from multiple sites that included 869 patients with OUD.

View Article and Find Full Text PDF
Article Synopsis
  • The study is focused on the increasing issue of hospitalizations related to opioid use disorder (OUD), comparing standard addiction consultation services to a specific treatment involving a long-lasting buprenorphine injection to improve post-hospital care engagement.
  • Patients in six U.S. hospitals who were not on medication for OUD before admission will be randomly assigned either to continue usual care or receive a single dose of a 28-day extended-release buprenorphine upon discharge.
  • Outcomes will be assessed at multiple follow-up points, with the primary goal of seeing if the XR-BUP group shows higher engagement in ongoing treatment 34 days after leaving the hospital, while also monitoring for safety and various secondary effects.
View Article and Find Full Text PDF

Objective: Opioid toxicity continues to have significant morbidity and mortality in Alberta. Opioid agonist therapy is an effective treatment for opiate use disorder (OUD), with first-line treatment with buprenorphine-naloxone (BUP-NAL) being both highly effective and safe. Barriers to care limit access to treatment, and more access points for treatment are needed.

View Article and Find Full Text PDF

Trends in injectable buprenorphine prescribing in Canada: A descriptive analysis in five Canadian Provinces.

Drug Alcohol Depend

November 2024

Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada; ICES, Toronto, Canada; Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Canada; Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada. Electronic address:

Article Synopsis
  • Injectable extended-release buprenorphine (BUP-ER) was introduced in Canada in February 2020, offering a new option for opioid agonist therapy (OAT), and this study examines its uptake across five provinces until March 2022.
  • A total of 6,528 individuals received BUP-ER, mainly in British Columbia and Ontario, with usage rates highest in British Columbia (16.6 per 100,000 population) and lowest in Ontario (9.1 per 100,000).
  • The study found greater BUP-ER usage in rural areas compared to urban settings and noted significant variations in the number of prescribers per 100,000 population across provinces, indicating differing access to
View Article and Find Full Text PDF

The prevalence of treatment-resistant depression within global and military populations highlights the need for novel treatment approaches beyond monoamine neurotransmitter modulators. Buprenorphine (BUP), a semi-synthetic partial opioid agonist, is approved for the treatment of opioid use disorder and has shown promise in treating both depression and chronic pain. This case report discusses the use of transdermal BUP in treating a 36 year-old man with treatment-resistant depression with prominent anhedonia, military-related posttraumatic stress disorder, and chronic pain because of barosinusitis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!